EUVIMEDEUVIMED entdecken
Open Access

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells

Daria Bulanova iD, Yevhen Akimov iD, Wojciech Senkowski iD, Jaana Oikkonen iD, Laura Gall-Mas iD, Sanna Timonen iD, Manar Elmadani, Johanna Hynninen iD, Sampsa Hautaniemi iD, Tero Aittokallio iD, Krister Wennerberg iD

Science Advances · 24.05.2024 · 10 (21)

DOI: 10.1126/sciadv.adj1564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 24.05.2024. Verfasst von Daria Bulanova und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Casein Kinase II, Retinoblastoma Binding Proteins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to therapy commonly develops in patients with high-grade serous ovarian carcinoma (HGSC) and triple-negative breast cancer (TNBC), urging the search for improved therapeutic combinations and their predictive biomarkers. Starting from a CRISPR knockout screen, we identified that loss of RB1 in TNBC or HGSC cells generates a synthetic lethal dependency on casein kinase 2 (CK2) for surviving the treatment with replication-perturbing therapeutics such as carboplatin, gemcitabine, or PARP inhibitors. CK2 inhibition in RB1-deficient cells resulted in the degradation of another RB family cell cycle regulator, p130, which led to S phase accumulation, micronuclei formation, and accelerated PARP inhibition–induced aneuploidy and mitotic cell death. CK2 inhibition was also effective in primary patient-derived cells. It selectively prevented the regrowth of RB1-deficient patient HGSC organoids after treatment with carboplatin or niraparib. As about 25% of HGSCs and 40% of TNBCs have lost RB1 expression, CK2 inhibition is a promising approach to overcome resistance to standard therapeutics in large strata of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Casein Kinase IIRetinoblastoma Binding ProteinsHumansFemaleCell Line, TumorTriple Negative Breast NeoplasmsOvarian NeoplasmsUbiquitin-Protein LigasesCarboplatinSynthetic Lethal MutationsDNA ReplicationDrug Resistance, NeoplasmPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic Agents

Substanzen

Casein Kinase IIRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesCarboplatinPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
  • Institute for Molecular Medicine Finland, Helsinki Institute for Life Sciences, University of Helsinki, Helsinki, Finland.
  • Research Program in Systems Oncology (ONCOSYS), University of Helsinki, Helsinki, Finland.
  • Finnish Red Cross Blood Service, Helsinki, Finland.
  • Department of Obstetrics and Gynecology, Turku University Hospital and University of Turku, Turku, Finland.
  • Institute for Cancer Research, Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Daria Bulanova, Yevhen Akimov, Wojciech Senkowski, Jaana Oikkonen, Laura Gall-Mas, Sanna Timonen, Johanna Hynninen, Sampsa Hautaniemi, Tero Aittokallio, Krister Wennerberg

Zitieren

APA

Bulanova, D., Akimov, Y., Senkowski, W., Oikkonen, J., Gall-Mas, L., Timonen, S., Elmadani, M., Hynninen, J., Hautaniemi, S., Aittokallio, T., & Wennerberg, K. (2024). A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells. Science Advances, 10(21). https://doi.org/10.1126/sciadv.adj1564

Vancouver

Bulanova D, Akimov Y, Senkowski W, Oikkonen J, Gall-Mas L, Timonen S, et al. A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells. Science Advances. 2024;10(21). doi:10.1126/sciadv.adj1564

BibTeX
@article{Bulanova2024,
  author = {Bulanova, Daria and Akimov, Yevhen and Senkowski, Wojciech and Oikkonen, Jaana and Gall-Mas, Laura and Timonen, Sanna and Elmadani, Manar and Hynninen, Johanna and Hautaniemi, Sampsa and Aittokallio, Tero and Wennerberg, Krister},
  title = {A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells},
  journal = {Science Advances},
  year = {2024},
  volume = {10},
  number = {21},
  doi = {10.1126/sciadv.adj1564}
}
Kostenlos starten →